Takeaways: Boehringer Ingelheim’s Jascayd authorization introduces a new mechanism into Canada’s IPF and PPF markets, potentially reshaping competition in fibrotic lung disease. Phase III ...
Browsing Tag: PDE4B inhibitor
Takeaways: Boehringer Ingelheim’s Jascayd authorization introduces a new mechanism into Canada’s IPF and PPF markets, potentially reshaping competition in fibrotic lung disease. Phase III ...